Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Revvity, Inc. is set to unveil its new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist™ ...

Revvity, Inc. (NYSE: RVTY), announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life ...

Jan 31 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...

Life sciences company Revvity (NYSE:RVTY) in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the ...

Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. At Revvity, “impossible” is inspiration ...

KeyBanc analyst Paul Knight maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. The company’s shares closed last Friday at $126.13. Leverage ...

Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year ...